Salmon Calcitonin

Therapeutic

Treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments; emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified; added to existing therapeutic regimens for hypocalcemia; in patients with azotemia; for treatment of post-menopausal osteoporosis.

Structural features

SMILES

CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(N)=O

Sequence

CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-NH2

Molar mass

3431.9 g/mol

Constitutional members:

32

Natural amino acids

32

D-Amino acids

0

N-terminus

H

C-terminus

NH2

Cyclic

yes

Members/cycle

7

Bond to form cycle

side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

NASAL Spray, IM, SC

Terminal half-life

59-64min (SC), 58min (IM), 18-23min (NS)

Protein binding

30-40%

Absorption and Bioavailability

71% (SC), 66% (IM), 3-5% (NASAL)

References